JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
The Vatican has launched a meticulous three-month restoration of Michelangelo's iconic 'Last Judgment' fresco in the Sistine Chapel, aiming to revive the masterpiece's original chromatic brilliance obscured by decades of grime.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
The famed Pennsylvania groundhog saw his shadow on Gobbler's Knob, forecasting a prolonged winter season as thousands braved the cold for the iconic ceremony, while meteorologists warn of ongoing cold spells across the eastern U.S.
Seventeen-year-old Hailey Buzbee vanished after leaving her Vermillion home in early January. Authorities now believe she is deceased and have arrested a man she met through online gaming, though murder charges have not yet been filed.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Amphenol Corporation (NYSE: APH), a key player in electronic connectors, received concurrent price target increases from Seaport Research and Citi. While analysts highlight growth potential, the stock's post-earnings dip underscores a cautious market stance toward the company's traditionally conservative guidance.
The renewable energy firm's latest quarterly results, described as a 'beat and raise,' have prompted major banks to lift their valuations, signaling strong confidence in its growth trajectory within the clean energy sector.
Pzena Investment Management's Focused Value Strategy lagged behind its benchmark in Q4 2025, with semiconductor firm Skyworks Solutions cited as a key detractor. The fund's commentary highlights the challenges for value investing in a market dominated by AI and mega-cap stocks.
Shares of the packaged food giant have slumped over the past year, raising questions about whether the stock is a bargain or a value trap. A deep dive into valuation metrics suggests significant upside potential.
Oppenheimer and Wells Fargo have raised price targets for Monolithic Power Systems (MPWR), highlighting robust demand from the automotive and artificial intelligence sectors as key growth drivers ahead of the company's quarterly results.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
A Milton, Massachusetts man's attempt to clear roof ice with a blowtorch during a severe winter storm sparked a fast-moving attic fire, prompting warnings from officials about the dangers of DIY ice removal.
While Automatic Data Processing (NASDAQ:ADP) has delivered solid earnings growth over five years, its share price appreciation has notably lagged the broader market. A deeper look reveals dividends have bolstered total returns, but recent underperformance highlights investor caution toward the payroll giant.
Investment firm Curreen Capital, known for targeting undervalued 'ugly duckling' companies, highlighted contract research organization Fortrea Holdings as a prime example of its strategy in its latest investor letter. The firm reported a 30.97% return for 2025.
Despite navigating a major venue overhaul, the Atlanta Shoe Market reports a 7% surge in pre-registrations, with brands and buyers adapting to a reimagined show floor that may boost visibility for some exhibitors.
